Evolving strategies in lung transplantation for emphysema.
Evolving strategies of pulmonary preservation, bronchial revascularization, immunosuppression, and infectious disease management were used in 15 initial consecutive patients undergoing lung transplantation for emphysema. There were 10 women and 5 men with a mean age of 49 years (range, 36 to 60 years). All patients required supplemental oxygen therapy. One bilateral, 9 left, and 5 right transplantations were performed. Mean preoperative forced expiratory volume in 1 second and total lung capacity were 16% and 146%, respectively, of predicted. Quadruple drug immunosuppression was used. Actuarial 1-year survival in this initial series is 93.3% +/- 6.4% (Kaplan-Meier) with one early cardiac death at day 71. Mean forced expiratory volume in 1 second and diffusing capacity for carbon monoxide at discharge were 43% and 62%, respectively, of predicted. Rehabilitation has been excellent, and all survivors are active and free of supplemental oxygen. During the study, the following treatment strategies have evolved: (1) University of Wisconsin solution has replaced Euro-Collins' solution for pulmonary preservation; (2) direct bronchial revascularization with the internal thoracic artery now is used; (3) an algorithm-based variable dose OKT3 induction regimen has resulted in a major reduction in dosage; and (4) infectious disease management focuses on the prophylaxis of cytomegalovirus and fungal infection using prolonged ganciclovir and early itraconazole therapy as well as the avoidance of Epstein-Barr virus mismatches. Single-lung transplantation for emphysema has excellent early results with continuing evolving management strategies.
McGregor
C G
CG
Department of Surgery, Mayo Clinic, Rochester, Minnesota 55905.
Daly
R C
RC
Peters
S G
SG
Midthun
D E
DE
Scott
J P
JP
Allen
M S
MS
Tazelaar
H D
HD
Keating
M R
MR
Walker
R C
RC
McDougall
J C
JC
D000241:Adenosine / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000493:Allopurinol / Q000627:therapeutic use; D000714:Anastomosis, Surgical; D001980:Bronchi / Q000473:pathology / Q000601:surgery; D001981:Bronchial Arteries / Q000473:pathology; D017079:Exercise Tolerance; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D005978:Glutathione / Q000627:therapeutic use; D006084:Graft Rejection / Q000209:etiology; D006801:Humans; D006982:Hypertonic Solutions / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D016040:Lung Transplantation / Q000009:adverse effects / Q000379:methods* / Q000502:physiology; D008232:Lymphoproliferative Disorders / Q000209:etiology; D008297:Male; D008875:Middle Aged; D019188:Organ Preservation Solutions; D010100:Oxygen / Q000097:blood; D010102:Oxygen Inhalation Therapy; D011030:Pneumothorax / Q000209:etiology; D011653:Pulmonary Diffusing Capacity / Q000502:physiology; D011656:Pulmonary Emphysema / Q000601:surgery* / Q000628:therapy; D011887:Raffinose / Q000627:therapeutic use; D013530:Surgical Wound Infection / Q000209:etiology; D015996:Survival Rate; D014021:Tissue Preservation
C037096:Euro-Collins' solution; D006982:Hypertonic Solutions; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose; D010100:Oxygen